Market Access & Commercialization
Delivering Your Success in the Taiwan Market
Taiwan’s healthcare and medical industry is one of the most advanced and mature in Asia. With a 99.9% coverage rate under the National Health Insurance (NHI) system and a steadily increasing enrollment in private insurance, Taiwan offers an exceptional market opportunity for pharmaceutical and medical device companies worldwide—particularly for innovative startups.
At the same time, the high coverage rate of NHI presents unique challenges. Acceleration regulatory approval and timely reimbursement submission are critical factors for successful market entry. Prior to obtaining reimbursement, establishing a presence in the self-pay market through strategic product launches and promotions provides a strong foundation for future inclusion under NHI.
ReneMed is led by a management team comprised of former senior executives from the leading global pharmaceutical companies. With extensive expertise in regulatory affairs, business development, market access and commercialization, we are uniquely positioned to support international companies in introducing their innovative medical products swiftly and successfully into the Taiwan market.
ReneMed Accelerating Taiwan Market Success
- Hospital listing & distribution